Pan-KRAS Degraders Effectively Target KRAS-Mutant Cancers

Major Finding: A small molecule degrader targets 13 of the most common oncogenic KRAS alleles in vitro and in vivo.Concept: ACBI3 is a proteolysis-targeting chimera that engages multiple oncogenic KRAS alleles with high affinity.Impact: This study provides preclinical proof of concept for the antitumor efficacy of pan-KRAS degradation.